SMS PHARMACEUTICALS
|
|
BOM : 532815     NSE : SMSPHARMA     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Oct 31,2024 |
Price(EOD): ₹ 294.60
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 2,495.26 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
SMS PHARMACEUTICALS | 4.9% | -21.4% | 149.4% |
SUN PHARMACEUTICAL INDUSTRIES | -0.6% | -3.7% | 66.1% |
CIPLA | 4.3% | -6.6% | 18.8% |
DR REDDYS LABORATORIES | -2.2% | -5.6% | 17% |
ZYDUS LIFESCIENCES | 1.2% | -7.3% | 70% |
DIVIS LABORATORIES | 2% | 8.7% | 73% |
MANKIND PHARMA | 8.5% | 3.5% | 49.9% |
TORRENT PHARMACEUTICALS | -6.9% | -5% | 62.8% |
LUPIN | 1.5% | -0.4% | 89.2% |
FUNDAMENTAL ANALYSIS OF SMS PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SMS PHARMACEUTICALS
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
43.93
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 56.76 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 4.91
P/B Calculated based on Book Value of Rs 507.75 Cr
[Latest Year - Mar2024 - Consolidated Results ] 3.38
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 738.38 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
969% 224% 189% |
SHARE PRICE MOMENTUM OF SMS PHARMACEUTICALS
SMS PHARMACEUTICALS vs SENSEX
DEBT OF SMS PHARMACEUTICALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.52 0.51 0.53 0.52 |
0.55 0.55 0.55 0.55 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF SMS PHARMACEUTICALS
Pledged Promoter Shares |
19.51 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF SMS PHARMACEUTICALS
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-33.1% -0.32% 0.42% 2% |
21.51% 27.99% 72.13% 85.9% |
QtrlyTrend |
4 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
SMS PHARMACEUTICALS related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE SMALL CAP | 2.5% | -3.8% | 49.1% |
S&P BSE HEALTHCARE | 2.4% | -0.7% | 61% |
S&P BSE MIDSMALLCAP | 1.1% | -5.3% | 48.5% |
S&P BSE ALLCAP | -0.3% | -6.3% | 35.7% |
You may also like the below Video Courses
FAQ about SMS PHARMACEUTICALS
Is SMS PHARMACEUTICALS good for long term investment?
As on Oct 31,2024, the Fundamentals of SMS PHARMACEUTICALS look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of SMS PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SMS PHARMACEUTICALS UnderValued or OverValued?
As on Oct 31,2024, SMS PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of SMS PHARMACEUTICALS ?
As on Oct 31,2024, the Intrinsic Value of SMS PHARMACEUTICALS is Rs. 91.02 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 27.55
Fair Value [Median EV / Sales Model] : Rs. 91.02
Fair Value [Median Price / Sales Model] : Rs. 101.81
Estimated Median Fair Value of SMS PHARMACEUTICALS : Rs. 91.02
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.